FDA ’s February oncology surge brings new pancreatic TTFields, PD-1 win in ovarian cancer, AI tools, and key trial setbacks.
March 2026 Targeted Pulse
This week in oncology: FDA approves relacorilant for ovarian cancer, clinical data for lung and GI cancers, and a faster thawing method for bladder cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Deep Responses Support Push for CAR T-Cell Therapy in AL Amyloidosis
2
FDA Approves Palbociclib Plus Anti-HER2 and Endocrine Therapy as Maintenance in Breast Cancer
3
Phase 3 TRIDENT Trial Misses Survival End Point in Glioblastoma
4
Gene Signature Predicts Anthracycline Benefit in HR+/HER2– Breast Cancer
5